Atlas Trials

Gemcitabine, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer After Prior Trastuzumab/Pertuzumab, or Pertuzumab Based Therapy

Clinical trial NCT02252887 · COMPLETED

Trial details

NCT number
NCT02252887
Sponsor
Memorial Sloan Kettering Cancer Center
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Metastatic HER2-Positive Breast Cancer
Start date
2015-01-12
Primary completion
2025-07-24
Enrollment
45

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.